Search

Displaying results 5481 - 5490 of 7540 in total
  1. Drug

    Parasorbic acid

    go.drugbank.com/drugs/DB14121
    Investigational

    Sole constituent of "Vogelbeerol" oil obtained by steam distillation of the acidified juice of the ripe berries of the mountain ash.

  2. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

    Synonyms: trans NV-04
  3. Drug

    Silver nitrate

    go.drugbank.com/drugs/DB11080
    Approved

    It is often used as a precursor to other silver-containing compounds.

  4. Drug

    Bifonazole

    go.drugbank.com/drugs/DB04794
    Approved

    Bifonazole is an azole antifungal drug.

    Products: LOTRIMIN-UNO
  5. Drug

    Pentaglobin

    go.drugbank.com/drugs/DB15865
    Investigational

    [A220173] It is comprised of [immunoglobulin G (IgG)](https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).[L16353]

  6. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).

  7. Drug

    Fexapotide

    go.drugbank.com/drugs/DB05493
    Investigational

    NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. … Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).

  8. Drug

    Methscopolamine

    go.drugbank.com/drugs/DB11315
    Approved

    The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.

  9. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … PLN-74809 is a small-molecule that dually inhibits both α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC

  10. Drug

    Alvespimycin

    go.drugbank.com/drugs/DB12442
    Investigational

    In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility